0940 GMT - Bayer's fourth-quarter results beat sales and Ebitda expectations, Morgan Stanley analysts write. However, guidance came broadly in line, so limited changes to consensus estimates are expected, they add. By division, 2025 crop science and pharma guidance implies around 2% and 4% downside risk to divisional consensus Ebitda estimates, respectively, they say. There was limited updates on litigation, with Bayer confirming that it will file a petition for review with the U.S. Supreme Court on glyphosate claims. Meanwhile, a ruling from the Washington Supreme Court for the Erickson case--which relates to claims of personal injury related to alleged PCB exposure--is expected in the coming months. Shares rise 5.3%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 05, 2025 04:40 ET (09:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。